New Trial Tests a JAK-Inhibitor Drug That Targets the Immune Signal Driving IBM Inflammation
In IBM, a specific immune alarm signal called interferon-gamma (IFN-γ) keeps muscle-damaging immune cells switched on. That signal travels through a pathway called JAK/STAT — the same pathway highlighted in a new study of IL-6 inflammation in IBM that we covered last week. Now a clinical trial is testing a drug that blocks this exact signaling route.
What the Trial Tests
The study — sponsored by Assistance Publique–Hôpitaux de Paris and running at 21 hospital centers across France — is a phase 2b randomized, placebo-controlled trial. It is recruiting about 80 adults aged 45 and older with a confirmed diagnosis of IBM. Participants are randomly assigned to receive either ruxolitinib (15 mg twice a day) or a matching placebo for one year.
Ruxolitinib is a JAK1/JAK2 inhibitor, a class of drug already approved for other conditions such as myelofibrosis. By blocking the JAK/STAT pathway, it aims to turn down the interferon-gamma signal and calm the type of immune attack that damages IBM muscle.
How They Will Measure Whether It Works
The main measurement is the six-minute walk test — how far participants can walk in six minutes — compared against placebo after a year of treatment. The trial will also track muscle strength, functional scales, breathing tests, and muscle MRI to build a fuller picture of any effect.
Who Can Take Part
The trial is recruiting now in France. To be eligible, people must have definite IBM — weakness in the finger flexors or quadriceps plus characteristic biopsy findings — and be able to walk for six minutes, with or without a walking aid. People already taking immunosuppressants, JAK inhibitors, or certain other medications, and people with significant heart, kidney, liver, or blood conditions, are excluded.
What This Means
This is a phase 2b trial, so it will tell us whether the approach is worth pursuing — not whether it works for everyone. It is the first large controlled trial of this drug in IBM, and it follows lab evidence that JAK-inhibitor treatment can prevent key IBM disease features in muscle-cell models. For patients, it is another sign that the JAK/STAT pathway is now a mainstream target in IBM drug development.
Full trial details — including the complete list of French study centers — are available on ClinicalTrials.gov under the identifier NCT06536166. Anyone considering taking part should discuss eligibility with their neurologist. Because the trial is currently recruiting only in France, patients elsewhere may want to follow its results.
Source
• "Ruxolitinib Treatment in Inclusion Body Myositis." ClinicalTrials.gov, NCT06536166. https://clinicaltrials.gov/study/NCT06536166
Tags
Related Reading
- Early Stage Tips — Exercise, energy conservation, and specialist directories
- Bathroom & Toileting — Equipment, bidets, and transfer techniques
- Travel Tips — Airlines, hotels, and emergency preparedness
- General Tips — Insurance, disability benefits, and support groups